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Patients with rheumatoid arthritis often develop methotrexate-associated lym-
phoproliferative disorders (MTX-LPD) during MTX treatment. MTX-LPD occasion-
ally regresses spontaneously after simply discontinuing MTX treatment. In
patients without spontaneous regression, additional chemotherapy is required to
avoid disease progression. However, the differences between spontaneous and
non-spontaneous regression have yet to be elucidated. To clarify the factors
important for spontaneous regression, we analyzed the clinicopathological fea-
tures of 51 patients with rheumatoid arthritis who developed MTX-LPD (diffuse
large B-cell lymphoma [DLBCL]-type [n = 34] and classical Hodgkin lymphoma
[CHL]-type [n = 17]). We examined the interval from MTX discontinuation to the
administration of additional chemotherapy. The majority of DLBCL-type MTX-LPD
patients (81%) exhibited remission with MTX discontinuation alone. In contrast,
the majority of CHL-type MTX-LPD patients (76%) required additional chemother-
apy. This difference was statistically significant (P = 0.001). However, overall sur-
vival was not significantly different between DLBCL-type and CHL-type (91% vs
94%, respectively; P > 0.05). Thus, the morphological differences in the patholog-
ical findings of MTX-LPD may be a factor for spontaneous or non-spontaneous
regression after discontinuation of MTX.
M ethotrexate (MTX) is an anti-cancer agent that is classi-fied as an anti-folate and is used as an anti-rheumatic
drug. MTX-associated lymphoproliferative disorders (MTX-
LPD) is a lymphoproliferative disease or lymphoma in
patients treated with MTX for autoimmune diseases, such as
rheumatoid arthritis (RA).(1) MTX-LPD was first reported in
1991 and was subsequently established as a disease concept
owing to the reported increase in incidence with the increas-
ing use of MTX for the treatment of RA.(2) MTX-LPD is
classified as “other iatrogenic immunodeficiency-associated
LPDs” in the 4th edition of the World Health Organization
classification.(2)
MTX-LPD have various histopathological features. Among
patients treated with MTX, the most commonly reported cases
are diffuse large B-cell lymphoma (DLBCL; 35–60%) and
classical Hodgkin lymphoma (CHL; 12–25%)-types.(2) There
are no histological differences compared with the lymphomas
of RA patients who develop non-MTX-LPD.(2,3)
Although the developmental mechanism of MTX-LPD is
poorly understood, it is assumed that immune disorders in
patients with RA and immunosuppression associated with
MTX might contribute to the development of MTX-LPD. In
the majority of patients with MTX-LPD, activation of the
Epstein-Barr virus (EBV) has been detected,(3,4) EBV-positive
patients, and some other patients with MTX-LPD, experience
spontaneous regression of their lesions after simply discontinu-
ing MTX treatment.(5–7) In patients with MTX-LPD that do
not spontaneously regress, additional chemotherapy is required
to avoid disease progression.(7) However, the differences
between spontaneous and non-spontaneous regression have yet
to be elucidated.
To clarify the factors important for spontaneous regression,
we examined the histopathological features, IGH gene rear-
rangements, EBV-encoded small RNA (EBER)-positive rates,
and the clinical course of RA patients who developed DLBCL-
type or CHL-type MTX-LPD.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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Patients and Methods
Patients. We analyzed the clinicopathological features of 51
patients who had been diagnosed with MTX-LPD (DLBCL-
type [n = 34] and CHL-type [n = 17]) and whose records
were selected from pathology files in the Department of
Pathology at Okayama University (Okayama, Japan). We
excluded patients with polymorphous-type MTX-LPD.
All patients received low-dose MTX, and 17 patients (33%)
received MTX with prednisolone. Five DLBCL-type and 4
CHL-type MTX-LPD patients were treated with MTX in com-
bination with other disease-modifying anti-rheumatic drugs
(e.g., infliximab, etanercept, adalimumab, and bucillamine). In
this study, 19 DLBCL-type (56%) and 12 CHL-type MTX-
LPD patients (71%) were included in the analysis of MTX
administration. The median treatment duration was 119 (range,
8–192) months.
This study was approved by the Institutional Review Board
of Okayama University (Okayama, Japan).
Clinical data. Data regarding the Eastern Cooperative Oncol-
ogy Group performance status and clinical stage (CS) were
collected from medical records.
Histological examination and in situ hybridization. Specimens
were fixed in 10% formaldehyde and embedded in paraffin.
Three-micrometer-thick sections were cut from the paraffin-
embedded tissue blocks and stained with hematoxylin and
eosin.
Paraffin sections of each tissue sample were used for
immunohistochemical staining with antibodies to CD3 (clone:
LN10, 1:200; Novocastra Laboratories, Ltd., Newcastle upon
Tyne, UK), CD5 (clone: 4C7, 1:100; Novocastra Laboratories,
Ltd.), CD10 (clone: 56C6, 1:100; Novocastra Laboratories,
Ltd.), CD15 (clone: Carb-3, 1:50; DAKO, Glostrup, Denmark),
CD20 (clone: L26, 1:100; DAKO), CD30 (clone: Ber-H2,
1:40; DAKO), EBV nuclear antigen 2 (EBNA2) (clone: PE2,
1:100; Abcam, Cambridge, MA, USA), EBV latent membrane
protein 1 (LMP-1) (clone: CS1-4, 1:50; Novocastra Laborato-
ries, Ltd.), and Ki-67 (clone: MIB-1, 1:2500; DAKO). Staining
was performed using the automated Bond Max Stainer (Leica
Biosystems, Wetzlar, Germany).
The EBV was detected by in situ hybridization for
EBER using the automated Bond Max Stainer (Leica
Biosystems).
IGH gene rearrangement analysis. We scraped sections from
the tumor area and placed them in 19 AmpliTaq Gold Buffer
(Applied Biosystems, Inc., Foster City, CA, USA). DNA was
extracted by incubating at 94°C for 45 min, using the auto-
mated Thermocycler GeneAmp PCR System 9700 (Applied
Biosystems, Inc.). DNA was quantified using the NanoDrop
ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc.,
Waltham, MA, USA). IGH gene rearrangement analysis was
performed as previously described.(8) The following primers
were used in this study:
VH1-FR2 (50-CTGGGTGCGACAGGCCCCTGGACAA-30),
VH2-FR2 (50-TGGATCCGTCAGCCCCCAGGGAAGG-30),
VH3-FR3 (50-GGTCCGCCAGGCTCCAGGGAA-30),
VH4-FR2 (50-TGGATCCGCCAGCCCCCAGGGAAGG-30),
VH5-FR2 (50-GGGTGCGCCAGATGCCCGGGAAAGG-30),
VH6-FR2 (50-TGGATCAGGCAGTCCCCATCGAGAG-30),
VH7-FR2 (50-TTGGGTGCGACAGGCCCCTGGACAA-30),
and JH consensus primer (50-CTTACCTGAGGAGACGGTGA
CC-30). The JH consensus primer was fluorescently labeled.
All primers were purchased from Sigma-Aldrich (Sigma-
Aldrich Japan, Tokyo, Japan). PCR products were analyzed
using an ABI PRISM 310 Genetic Analyzer with GeneScan
Analysis and GeneMapper software (Applied Biosystems,
Inc.). IGH gene rearrangements were analyzed and evaluated
using the BIOMED-2 protocol.(8) If the waveform of the PCR
product could be confirmed, even by a small amount, this find-
ing was interpreted as polyclonal expression. If a peak was not
visible (e.g., due to sample condition) then these samples were
deemed to have undetectable expression.
Statistical analyses. Differences between DLBCL-type and
CHL-type MTX-LPD were determined using Student’s t and v2
tests. A P < 0.05 was considered statistically significant. Over-
all survival was defined as the time from the date of diagnosis
of a MTX-LPD to the date of death or last follow-up. Progres-
sion-free survival was defined as the time from the date of
diagnosis of a MTX-LPD to the date of commencing
chemotherapy or the date of death or last follow-up. The fol-
low-up duration was calculated as the time from the date of
diagnosis of a MTX-LPD to the date of death from any cause
or last follow-up. The duration from the date of diagnosis of a
MTX-LPD to the date of commencing chemotherapy was deter-
mined. Survival curves were generated using the Kaplan-Meier
method. All statistical analyses were conducted using SPSS for
Windows software version 14.0 (SPSS Inc., Chicago, IL, USA).
Results
Comparison of the clinicopathological features between
patients with DLBCL-type and CHL-type MTX-LPD. Of the 51
patients with a MTX-LPD, 34 patients (67%) had a DLBCL-
type MTX-LPD and 17 patients (33%) had a CHL-type
MTX-LPD. The median age of the entire cohort was 67
(range, 45–84) years, and the median age did not differ
between the MTX-LPD subtypes (Table 1). The male-to-
female ratio of the entire cohort was 14:37 and the proportion
of female patients was high for both MTX-LPD subtypes.
Reduced hemoglobin levels of <10.5 g/dL were observed in
30% (9/30) patients with a DLBCL-type MTX-LPD and 46%
(6/13) patients with a CHL-type MTX-LPD. A reduction in
the total lymphocyte count was observed in 34% (10/29)
patients with a DLBCL-type MTX-LPD and 23% (3/13)
patients with a CHL-type MTX-LPD. The median soluble
interleukin 2 receptor value was 2,748 IU/mL for the DLBCL-
type MTX-LPD (n = 30) and 2,450 IU/mL for the CHL-type
MTX-LPD (n = 15).
The Eastern Cooperative Oncology Group performance
status was not significantly different between the MTX-LPD
subtypes (P > 0.05). Twelve patients with a DLBCL-type
MTX-LPD and five patients with a CHL-type MTX-LPD had
an Eastern Cooperative Oncology Group performance status of
≥2. CS was also not significantly different between the MTX-
LPD subtypes (P > 0.05). Twenty-five patients with a
DLBCL-type MTX-LPD and 13 patients with a CHL-type
MTX-LPD had a CS of ≥3 (Table 1).
Of the 17 patients with a CHL-type MTX-LPD, seven
patients (41%) had extranodal lesions in organs and tissues,
such as the brain, lungs, kidneys, liver, and bone marrow.
Histopathological classification. DLBCL-type MTX-LPD. Atyp-
ical lymphoid cells were large and revealed monomorphic prolif-
eration. The rates of positive immunohistochemical staining
for CD3, CD5, CD10, and CD20 were 0% (0/34), 0% (0/26), 5%
(1/22), and 88% (30/34), respectively (Fig. 1). A high Ki-67
labeling index of >30% (i.e., a high Ki-67 labeling index) was
observed for all of the cases with a DLBCL-type MTX-LPD.
The EBER-positive rate was 82% (28/34; Table 1).
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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Table 1. Clinical findings of patients with rheumatoid arthritis who developed methotrexate-associated lymphoproliferative disorders,
compared between diffuse large B-cell lymphoma-type and classical Hodgkin lymphoma-type
All patients (n = 51) DLBCL-type (n = 34) CHL-type (n = 17) P-value
Age 67 (45–84) 70 (55–82) 64 (45–84) 0.09
Sex (male:female) 14:37 10:24 4:13 0.46
PS ≥ 2 37% (17/46) 41% (12/29) 29% (5/17) 0.46
Clinical stage ≥3 75% (38/51) 74% (25/34) 76% (13/17) 0.55
High LDH levels 67% (33/49) 72% (23/32) 59% (10/17) 0.37
Extranodal disease 57% (29/51) 65% (22/34) 41% (7/17) 0.10
Extranodal disease ≥2 8 5 3 0.76
B symptom positive 53% (24/45) 57% (17/30) 47% (7/15) 0.38
EBER positive 82% (42/51) 82% (28/34) 82% (14/17) 0.66
Died 6 5 1
High lactate dehydrogenase (LDH) levels were defined as values equal to or greater than the reference value. DLBCL, diffuse large B-cell lym-
phoma; CHL, classical Hodgkin lymphoma; EBER, Epstein-Barr Virus-encoded small RNA in situ hybridization; MTX, methotrexate; PS, Eastern
Cooperative Oncology Group performance status.
Fig. 1. Histological findings of diffuse large B-cell
lymphoma-type methotrexate-associated lympho-
proliferative disorders. (a) Hematoxylin and eosin
staining at 4009 magnification (high-powered field).
Large atypical lymphoid cells exhibited
monomorphic proliferation. Tumor cells were (b)
CD20-positive, (c) CD3-negative, and (d) had a high
Ki-67 labeling index. Tumor cells were also (e)
positive for Epstein-Barr Virus-encoded small RNA
(EBER) in situ hybridization.
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CHL-type MTX-LPD. Hodgkin and Reed-Sternberg cells
were observed in a cellular background rich in non-neoplas-
tic small lymphocytes, histiocytes, and eosinophils. In the
Hodgkin and Reed-Sternberg cells, the rates of positive
immunohistochemical staining for CD3, CD15, CD20,
CD30, EBNA2, and LMP-1 were 0% (0/16), 60% (9/15),
29% (5/17), 100% (17/17), 0% (0/11), and 62% (8/13),
respectively (Fig. 2). The EBER-positive rate was 82% (14/
17; Table 1).
The EBV latent infection type was analyzed in the CHL-
type MTX-LPD cases. A type I infection (EBER-positive,
LMP-1-negative, and EBNA2-negative) was observed in two
cases, a type II infection (EBER-positive, LMP-1-positive, and
EBNA2-negative) in six cases, and a type III infection (EBER-
positive, LMP-1-positive, and EBNA2-positive) in 0 cases.
The EBV latent infection type was not available for the
remaining nine cases (Table 2).
IGH gene rearrangement. IGH gene rearrangements were
analyzed in 36 cases (DLBCL-type MTX-LPD [n = 27] and
CHL-type MTX-LPD [n = 9]). In the DLBCL-type MTX-
LPD, monoclonal rearrangements were detected in two cases
(7%) and polyclonal rearrangements were detected in 17 cases
(63%). In the CHL-type MTX-LPD, polyclonal rearrangements
were detected in five cases (56%). IGH gene rearrangements
were undetectable in the remaining cases.
Clinical course of patients with MTX-LPD after discontinuing
MTX treatment. CHL-type MTX-LPD. In all patients, the
administration of MTX had been discontinued at the time of
MTX-LPD diagnosis (Table 2). In four patients, the lesions
were reduced and were controllable after the discontinuation
of MTX treatment. Another seven patients showed regrowth
after reduction of the lesions and additional chemotherapy was
required. Relapse occurred in seven patients with a CHL-type
MTX-LPD. The median duration until relapse was 6.4 months.
Discontinuation of MTX treatment was ineffective in six
patients. These patients received chemotherapy for the CHL.
Therefore, additional chemotherapy was required in a total of
13 patients (76%). Of the 13 patients who required additional
Fig. 2. Histological findings of classical Hodgkin
lymphoma-type methotrexate-associated lympho-
proliferative disorders. (a) Hematoxylin and eosin
staining at 4009 magnification (high-powered
field). Hodgkin and Reed-Sternberg cells were
observed in a cellular background rich in
lymphocytes, histiocytes, and eosinophils. Tumor
cells were (b) CD30-positive and (c) CD15-positive.
(d) CD3-positive cells formed a rosette around the
Hodgkin and Reed-Sternberg cells. Tumor cells were
also (e) positive for Epstein-Barr Virus-encoded
small RNA (EBER) in situ hybridization.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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chemotherapy, 12 patients exhibited complete remission after
chemotherapy; one patient died of bacterial pneumonia during
chemotherapy (Table 3).
DLBCL-type MTX-LPD. Among the 34 patients with a
DLBCL-type MTX-LPD, MTX was discontinued in 27
patients at the time of MTX-LPD diagnosis. In 22 patients
(81%), remission of the lesions occurred after MTX was dis-
continued and additional chemotherapy was unnecessary. Only
one patient exhibited regrowth after reduction of the lesion.
The duration until relapse was 10.7 months. This patient died
without receiving chemotherapy after relapse. Four patients
required additional chemotherapy after the discontinuation of
MTX. Of these, three patients exhibited complete remission
after chemotherapy and one patient died of therapy-related
acute myeloid leukemia. The attending physician initiated
chemotherapy using the R-CHOP (rituximab, cyclophos-
phamide, doxorubicin, vincristine, prednisolone) regimen or
similar.
For five patients, chemotherapy was initiated at the same
time as the MTX-LPD was diagnosed. Of these, four patients
exhibited complete remission after chemotherapy and one
patient died of the MTX-LPD.
Two patients with a MTX-LPD were diagnosed at autopsy.
The cause of death was the MTX-LPD and gastrointestinal
bleeding (Table 4).
Progression-free survival analysis of patients with MTX-LPD.
The progression-free survival differed significantly between the
two MTX-LPD subtypes (12.1 vs 6.4 months for the DLBCL-
type and CHL-type, respectively; P = 0.001) (Fig. 3). The two
patients diagnosed at autopsy and the five patients who com-
menced chemotherapy at the time the MTX-LPD was diag-
nosed were excluded from this analysis.
Overall survival analysis of patients with MTX-LPD. The med-
ian overall survival did not differ significantly between the
two MTX-LPD subtypes (P > 0.05; Fig. 4). The two
patients diagnosed at autopsy were also excluded from this
analysis.
The median follow-up durations were 16.9 and 36.0 months
for patients with a DLBCL-type and CHL-type MTX-LPD,
respectively.
Discussion
In this study, we investigated the clinicopathological differ-
ences between patients with DLBCL-type (n = 34) and CHL-
type (n = 17) MTX-LPD. Overall, more female patients devel-
oped MTX-LPD, which might be related to the fact that RA is
more common among women.
In previous studies,(2,3,7,9,10) lesion reduction was observed
in 25–60% of the total number of patients after MTX was dis-
continued, and subsequent regrowth was reported in 18–45%
of patients. Comparatively, lesion reduction was observed in
34 patients (77%) in the present study, and regrowth was con-
firmed in eight patients (24%). Of the eight patients with
tumor regrowth, only the patient with a DLBCL-type MTX-
LPD died. The overall survival rates were comparable between
the DLBCL-type and CHL-type MTX-LPD and despite a high
CS the overall survival rates were good. These results were
consistent with those of previous reports.(7,9,11) The immune
deficiency owing to MTX administration helps to explain these
findings, and the clinical course of the DLBCL-type MTX-
LPD differs from that of non-MTX-associated DLBCL. In the
present study, the median follow-up durations of the DLBCL-
type and CHL-type MTX-LPD were 16.9 and 36.0 months,
respectively. In several previously published reports,(10) the
mean follow-up duration of MTX-LPD patients was 24.3
(range, 8–60) months. Given that there were patients who suf-
fered a relapse after remission was achieved by the discontinu-
ation of MTX, we think that further long-term observations are
required.
Table 3. Clinical course of classical Hodgkin lymphoma-type methotrexate-associated lymphoproliferative disorders after discontinuation of
methotrexate
Patient
No.
Response after
MTX
discontinuation
Regrowth after
MTX discontinuation
Period from
MTX-LPD diagnosis
to initiation of
chemotherapy (months)
Response to
chemotherapy
Final state Final
outcome
1 Exacerbation — 0.7 Progressive disease Bacterial pneumonia
during chemotherapy
Dead
2 Reduction Regrowth 7.3 Complete response CR state after the chemotherapy Alive
3 Exacerbation — 2.4 Complete response CR state after the chemotherapy Alive
4 Reduction Regrowth 5.7 Complete response CR state after the chemotherapy Alive
5 No change — 0.7 Complete response CR state after the chemotherapy Alive
6 No change — 0.5 Complete response CR state after the chemotherapy Alive
7 Reduction Regrowth 23.5 Complete response CR state after the chemotherapy Alive
8 No change — 0.5 Complete response CR state after the chemotherapy Alive
9 Reduction Regrowth 21.5 Complete response CR state after the chemotherapy Alive
10 Reduction None None — Spontaneous remission Alive
11 Reduction Regrowth 15.1 Complete response CR state after the chemotherapy Alive
12 Reduction Regrowth 9.5 Complete response CR state after the chemotherapy Alive
13 Reduction None None — Spontaneous remission Alive
14 No change — 0.9 Complete response CR state after the chemotherapy Alive
15 Reduction None None — Spontaneous remission Alive
16 Reduction None None — Spontaneous remission Alive
17 Reduction Regrowth 7.6 Complete response CR state after the chemotherapy Alive
CR, complete response; MTX, methotrexate; MTX-LPD, methotrexate-associated lymphoproliferative disorders.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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In this study, the majority of the 51 patients had a high CS;
the CS ≥ 3 in 25 patients (74%) with DLBCL-type MTX-LPD
and 13 patients (76%) with CHL-type MTX-LPD. In addition,
a large proportion of patients had extranodal lesions. Of the 17
patients with CHL-type MTX-LPD, seven patients (41%) had
extranodal lesions in organs and tissues, such as the brain,
lungs, kidneys, liver, and bone marrow. Non-MTX-associatedTa
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Fig. 3. Progression-free survival of patients with diffuse large B-cell
lymphoma-type or classical Hodgkin lymphoma (CHL)-type methotrex-
ate-associated lymphoproliferative disorders (MTX-LPD). Patients with
CHL-type MTX-LPD required additional chemotherapy because of no
response to the discontinuation of methotrexate.
Fig. 4. Overall survival of patients with diffuse large B-cell lym-
phoma-type or classical Hodgkin lymphoma-type methotrexate-asso-
ciated lymphoproliferative disorders. The difference in overall survival
was not statistically significant (P = 0.408).
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CHL is usually localized, most frequently involving the lymph
nodes of the cervical and mediastinal regions, and primary
extranodal involvement is rare.(12) However, iatrogenic immun-
odeficiency-associated CHL in patients with a high CS has fre-
quently been reported.(13) Because the high CS and extranodal
lesions with CHL-type MTX-LPD differ from the clinical find-
ings of non-MTX-associated CHL, they are considered charac-
teristic of CHL-type MTX-LPD.
Lesion regression as a result of simply discontinuing MTX
treatment occurs more frequently in EBER-positive cases than
EBER-negative cases.(4,14,15) Since the majority of both
DLBCL-type and CHL-type MTX-LPD cases were EBER-po-
sitive, we were unable to compare the prognoses of EBER-
positive and EBER-negative patients. However, the
EBER-positive rate for the DLBCL-type MTX-LPD was higher
(82%) than that reported previously (40–60%).(3,4,7,9,11,15)
EBV infection usually exhibits a type II latency pattern.
Among the CHL-type MTX-LPD cases in the present study,
six cases exhibited a type II latency pattern, while two cases
exhibited a type I latency pattern. Although we cannot explain
the reason for the type I latency pattern, similar results were
reported by Loo et al.(13), and the cause may be related to the
MTX-LPD. We could not analyze the type of EBV latent
infection in DLBCL-type MTX-LPD patients because of sam-
ple limitations. However, according to previous reports,(6,7) the
EBV latency pattern of the DLBCL-type MTX-LPD may be
identical to that of the CHL-type MTX-LPD.
According to the 4th edition of the World Health Organiza-
tion classification system,(2) the immunophenotype of iatro-
genic immunodeficiency-associated LPD does not appear to
differ from that of comparable histological subtypes of lym-
phoma in non-immunosuppressed hosts.(2) Five patients with
CHL-type MTX-LPD (29%) in the present study were CD20-
positive. This finding is frequently observed in CHL-type
MTX-LPD.(2,16)
Regarding IGH gene rearrangements, monoclonality of IGH
is frequently observed in DLBCL-type MTX-LPD, and MTX-
LPD patients with monoclonality had an unfavorable prognosis
in a previous study.(7) Interestingly, however, although all
DLBCL-type MTX-LPD cases exhibited monomorphic prolif-
eration in the present study, of the 36 patients for whom IGH
gene rearrangements were analyzed, only two DLBCL-type
MTX-LPD cases exhibited monoclonality, with the majority of
cases exhibiting polyclonal multiplication. Therefore, although
we were unable to compare prognoses, the lesions in the two
cases with monoclonal rearrangement were not reduced after
discontinuing MTX treatment. In the present study, the EBER-
positive rate was high and the IGH monoclonality rate was
low. The prognoses may have been good because of the high
EBER-positive rate.
There was a significant difference in the number of patients
who experienced remission after discontinuing MTX treatment
between DLBCL-type and CHL-type MTX-LPD. Immunomod-
ulatory agents were administered in combination with MTX in
nine patients (DLBCL-type MTX-LPD [n = 5] and CHL-type
MTX-LPD [n = 4]). The difference between the frequencies
of administration of immunomodulatory agents was not signifi-
cant (P > 0.05). Of the 27 DLBCL-type MTX-LPD patients
who discontinued MTX, 22 patients (81%) showed remission.
In contrast, discontinuing MTX treatment for CHL-type MTX-
LPD patients was ineffective for disease control in 13 patients
(76%) who then required additional chemotherapy. Chemother-
apy resulted in a good response. Additional chemotherapy was
required for iatrogenic immunodeficiency-associated Hodgkin
lymphoma patients in previous case reports.(3,13,15–21) In addi-
tion, the progression-free survival was significantly shorter in
CHL-type MTX-LPD patients than DLBCL-type MTX-LPD
patients.
A CHL-type MTX-LPD patient presented with a localized
gingival lesion. Although this lesion may be considered a
mucocutaneous ulcer, this patient exhibited tumor regrowth
after lesion reduction and required additional chemotherapy.
In conclusion, the histological subtype of MTX-LPD
(DLBCL-type vs CHL-type) may represent an important factor
for spontaneous or non-spontaneous regression after the dis-
continuation of MTX treatment.
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